London, UK; Brentwood, TN; 28 February 2007 - In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
London, UK; Brentwood, TN; 28 February 2007 - In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
